Annual EBITDA
-$148.63 M
-$37.38 M-33.60%
31 December 2023
Summary:
Akero Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$148.63 million, with the most recent change of -$37.38 million (-33.60%) on 31 December 2023. During the last 3 years, it has fallen by -$68.49 million (-85.47%). AKRO annual EBITDA is now -978.76% below its all-time high of -$13.78 million, reached on 31 December 2018.AKRO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$71.46 M
-$16.70 M-30.50%
30 September 2024
Summary:
Akero Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$71.46 million, with the most recent change of -$16.70 million (-30.50%) on 30 September 2024. Over the past year, it has dropped by -$32.69 million (-84.33%). AKRO quarterly EBITDA is now -16873.40% below its all-time high of -$421.00 thousand, reached on 31 March 2018.AKRO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$232.85 M
-$32.69 M-16.33%
30 September 2024
Summary:
Akero Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$232.85 million, with the most recent change of -$32.69 million (-16.33%) on 30 September 2024. Over the past year, it has dropped by -$115.82 million (-98.97%). AKRO TTM EBITDA is now -55209.26% below its all-time high of -$421.00 thousand, reached on 31 March 2018.AKRO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AKRO EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -33.6% | -84.3% | -99.0% |
| 3 y3 years | -85.5% | -193.8% | -137.3% |
| 5 y5 years | -978.8% | -338.1% | -618.7% |
AKRO EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -85.5% | at low | -215.0% | at low | -137.3% | at low |
| 5 y | 5 years | -978.8% | at low | -477.3% | at low | -618.7% | at low |
| alltime | all time | -978.8% | at low | <-9999.0% | at low | <-9999.0% | at low |
Akero Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$71.46 M(+30.5%) | -$232.85 M(+16.3%) |
| June 2024 | - | -$54.76 M(+4.6%) | -$200.16 M(+14.0%) |
| Mar 2024 | - | -$52.35 M(-3.6%) | -$175.62 M(+18.2%) |
| Dec 2023 | -$148.63 M(+33.6%) | -$54.29 M(+40.0%) | -$148.63 M(+27.0%) |
| Sept 2023 | - | -$38.77 M(+28.3%) | -$117.03 M(+3.1%) |
| June 2023 | - | -$30.21 M(+19.1%) | -$113.47 M(+2.6%) |
| Mar 2023 | - | -$25.36 M(+11.8%) | -$110.60 M(-0.6%) |
| Dec 2022 | -$111.25 M(+10.4%) | -$22.69 M(-35.6%) | -$111.25 M(-8.0%) |
| Sept 2022 | - | -$35.21 M(+28.8%) | -$120.98 M(+9.9%) |
| June 2022 | - | -$27.34 M(+5.1%) | -$110.09 M(-1.4%) |
| Mar 2022 | - | -$26.02 M(-19.7%) | -$111.67 M(+10.8%) |
| Dec 2021 | -$100.74 M | -$32.41 M(+33.3%) | -$100.77 M(+2.7%) |
| Sept 2021 | - | -$24.32 M(-15.9%) | -$98.13 M(+2.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | -$28.92 M(+91.3%) | -$95.34 M(+15.0%) |
| Mar 2021 | - | -$15.12 M(-49.2%) | -$82.88 M(+3.4%) |
| Dec 2020 | -$80.14 M(+75.5%) | -$29.77 M(+38.3%) | -$80.14 M(+20.4%) |
| Sept 2020 | - | -$21.53 M(+30.9%) | -$66.59 M(+8.5%) |
| June 2020 | - | -$16.45 M(+32.9%) | -$61.36 M(+16.8%) |
| Mar 2020 | - | -$12.38 M(-23.7%) | -$52.52 M(+15.0%) |
| Dec 2019 | -$45.65 M(+231.3%) | -$16.22 M(-0.5%) | -$45.65 M(+40.9%) |
| Sept 2019 | - | -$16.31 M(+114.3%) | -$32.40 M(+81.8%) |
| June 2019 | - | -$7.61 M(+38.0%) | -$17.82 M(-5.6%) |
| Mar 2019 | - | -$5.51 M(+85.7%) | -$18.87 M(+37.0%) |
| Dec 2018 | -$13.78 M | -$2.97 M(+71.9%) | -$13.78 M(+27.5%) |
| Sept 2018 | - | -$1.73 M(-80.1%) | -$10.81 M(+19.0%) |
| June 2018 | - | -$8.66 M(+1957.5%) | -$9.08 M(+2057.5%) |
| Mar 2018 | - | -$421.00 K | -$421.00 K |
FAQ
- What is Akero Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Akero Therapeutics?
- What is Akero Therapeutics annual EBITDA year-on-year change?
- What is Akero Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Akero Therapeutics?
- What is Akero Therapeutics quarterly EBITDA year-on-year change?
- What is Akero Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Akero Therapeutics?
- What is Akero Therapeutics TTM EBITDA year-on-year change?
What is Akero Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of AKRO is -$148.63 M
What is the all time high annual EBITDA for Akero Therapeutics?
Akero Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$13.78 M
What is Akero Therapeutics annual EBITDA year-on-year change?
Over the past year, AKRO annual earnings before interest, taxes, depreciation & amortization has changed by -$37.38 M (-33.60%)
What is Akero Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of AKRO is -$71.46 M
What is the all time high quarterly EBITDA for Akero Therapeutics?
Akero Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$421.00 K
What is Akero Therapeutics quarterly EBITDA year-on-year change?
Over the past year, AKRO quarterly earnings before interest, taxes, depreciation & amortization has changed by -$32.69 M (-84.33%)
What is Akero Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of AKRO is -$232.85 M
What is the all time high TTM EBITDA for Akero Therapeutics?
Akero Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$421.00 K
What is Akero Therapeutics TTM EBITDA year-on-year change?
Over the past year, AKRO TTM earnings before interest, taxes, depreciation & amortization has changed by -$115.82 M (-98.97%)